AAV9 Gene Replacement Therapy: The Quiet Hope for Ultra-Rare UBA5 Disorder

Genezen and the Raiden Science Foundation announced on August 3, 2026, a manufacturing partnership to advance an AAV9 gene replacement therapy toward a first-in-human clinical trial for UBA5 disorder. The collaboration combines Genezen's viral vector manufacturing expertise with the foundation's patient-driven advocacy for the ultra-rare neurodevelopmental condition. UBA5 disorder is caused by mutations in the UBA5 gene, which disrupts the cellular ubiquitination process essential for protein regulation. The progressive disease leads to a decline in cognitive and motor skills in children. AAV9 was selected for its ability to cross the blood-brain barrier and deliver genetic cargo to the central nervous system. Genezen provides the specialized infrastructure and quality control systems required to produce the complex biological agents at clinical scale. The Raiden Science Foundation pools resources and expertise to drive therapies forward for patient populations too small to attract traditional pharmaceutical investment. The partnership aims to address the root cause of the monogenic disorder by introducing a functional copy of the gene to produce the correct protein. No approved treatments currently exist for the condition, which affects fewer than a hundred children globally.